SEOUL, May 29 (AJP) - Celltrion has kicked off primate toxicity trials for its next-generation obesity drug candidate CT-G32, moving the compound into the final stretch of preclinical development ahead of a planned investigational new drug (IND) submission in the first half of 2026. CT-G32 simultaneously targets four biological pathways, including GLP-1, making it what Celltrion describes as a potential first-in-class therapy. The company said the drug is designed to address persist